IntroductionDaniel S. Chen, MD, PhD – IGM Biosciences

Mechanisms of Immune Escape to Checkpoint Inhibitors
Priti S. Hegde, PhD – Genentech, Inc.

A Novel Inflammasome-Wnt Ligand Signaling Axis Promotes Immune Escape During Anti-PD-1 Antibody Immunotherapy
Brent A. Hanks, MD, PhD – Duke University Medical Center 

Cell Proliferation Defines an Additional Mechanism of Immune Escape in Non-small Cell Lung Cancer
Grace Dy, MD – Roswell Park Comprehensive Cancer Center

Melanoma Tissue Microarray Characterization with Digital Spatial Profiling Identifies Biomarkers of Clinical Response to Immunotherapy
David Rimm, MD, PhD – Yale University

Primary and Secondary Mechanisms of Resistance to Autologous Anti-CD19 CAR T cell Therapy in Refractory Non-Hodgkin's Lymphoma (rNHL)
John Rossi, MD – Kite Pharma

Group Discussion

Break

Panel Discussion: Can CAR T cells Overcome and Influence Resistance to Other Treatment Modalities & New Concepts in Immune Checkpoint Blockade Designed to Overcome Local Immune Resistance
Co-Moderators: Adrian Bot, MD, PhD – Kite a Gilead Company
Eric H. Rubin, MD – Merck
Panelists: Daniel S. Chen, MD, PhD – IGM Biosciences
Gordon J. Freeman, PhD – Dana-Farber Cancer Center
Carl H. June, MD – University of Pennsylvania
Alan Korman, PhD – Bristol-Myers Squibb
Marcela Maus, MD, PhD – Massachusetts General Hospital

Analysis of TIL from Human Carcinoma Combined with Tissue Imaging and in vitro Models Uncovers Tumor-inflicted T Cell Deviations Related to Immune Escape and Strategies of Intervention
Elfriede Noessner, PhD – Helmholtz Zentrum Munchen

Impact of Tumor Inherent Interferons on Immune Reactivity and Personalized Therapy in Triple Negative Breast Cancer
Natasha K. Brockwell, BBiomed (Hons) – La Trobe Institute for Molecular Science

Repurposing Anti-Pathogen Vaccines to Overcome Immune Escape within the Tumor Microenvironment
Andrew Zloza, MD, PhD – Rutgers Cancer Institute of New Jersey

First in Human Data in Advanced Solid Tumors of NANT Cancer Vaccine: A Novel Temporospatial Orchestration of the Innate (NK) & Adaptive Immune System to Induce Antigen Cascade & Immunogenic Cell Death
Patrick Soon-Shiong – NANT Cancer Immunotherapy, Inc.

Group Discussion

Break

Panel Discussion: Immune Resistance and the Tumor Micronenvironment & Using Oncolytic Immunotherapy to Overcome Immune Resistance in the Tumor Microenvironment
Co-Moderators: Alessandra Cesano, MD, PhD – NanoString Inc.
Howard L. Kaufman, MD, FACS – Replimune Group Inc.
Panelists: Robert Coffin, PhD – Replimune Group Inc.
George Coukos, MD, PhD – University of Lausanne
Francesco M. Marincola, MD – Refuge Biotechnologies
Ira Mellman, PhD – Genentech/Roche
Ryan Sullivan, MD – Massachusetts General Hospital
Dmitriy Zamarin, MD, PhD – Memorial Sloan Kettering Cancer Center

Underlying Mechanisms of Immune Escape
Thomas F. Gajewski, MD, PhD – University of Chicago

Salil Patel, PhD – Bristol-Myers Squibb

Reception

Laurence Zitvogel, MD, PhD – Institute Gustave Roussy

Break

Harnessing Diet and the Microbiome for Cancer Patients and Survivors
Carrie Daniel-MacDougall, MPH, PhD – University of Texas MD Anderson Cancer Center

Homeostatic and Inflammatory Immune Responses to Human Microbiotas in Gnotobiotic Mice
Graham Britton, PhD – Icahn School of Medicine at Mount Sinai

The Interplay Between Diet, Intestinal Microbiota and Colorectal Cancer
Christian Jobin, PhD – University of Florida

Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine

Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine

Break

Cancer Vaccines : From Ex Vivo Production to In Vivo Vaccination
Tanja de Gruijl, PhD – VU University Medical Center

Break

Marc Theoret, MD – U.S. Food & Drug Administration, OHOP
Howard Kaufman, MD, FACS – Replimune Group, Inc.

Moderator: Marc Theoret, MD – U.S. Food & Drug Administration, OHOP 
Panelists: Peter Bross, MD – U.S. Food & Drug Administration, CBER, DCEPT
David Feltquate, MD, PhD – Bristol Myers Squibb
Sanjay Goel, MD – Montefiore Medical Center
Patricia Keegan, MD – U.S. Food and Drug Administration
Kim Margolin, MD – City of Hope
Steven Silverstein, MBA – Melanoma Research Foundation
Jon Wigginton, MD – MacroGenics, Inc.

Break

Genevieve Boland, MD, PhD – Massachusetts General Hospital

Moderator: Howard Kaufman, MD, FACS – Replimune Group Inc.
Panelists: Genevieve Boland, MD, PhD – Massachusetts General Hospital
Samir Khleif, MD – Georgetown University
Ke Liu, MD, PhD – U.S. Food and Drug Administration, CBER
David McDermott, MD – Beth Israel Deaconess Medical Center
Reena Philip, PhD – U.S. Food & Drug Administration
Meredith Regan, ScD – Dana-Farber Cancer Institute
Lawrence H. Schwartz, MD – Columbia University College of Physicians and Surgeons
Rajeshwari Sridhara, PhD – U.S. Food & Drug Administration

Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center
Ke Liu, MD, PhD – Food and Drug Administration, CBER

Melanoma Research Alliance (MRA)/Foundation Funding
Kristen Mueller, PhD – Melanoma Research Alliance

Presidential Champagne Toast & Membership Business Meeting

Lisa Butterfield, PhD – University of Pittsburgh

Introduction
Lisa H. Butterfield – University of Pittsburgh

Next Gen T Cell-based Immunotherapy
Nicholas Restifo, MD – National Cancer Institute

Introduction
Bernard A. Fox, PhD – Earle A. Chiles Research Institute, Robert W. Franz Cancer Center

Genomic Approaches to the Tumor Microenvironment
Alexandra Snyder Charen, MD – Merck

Understanding the Tumor Immune Composition Using Quantitative and Spatially Resolved Imaging Mass Cytometry
Kurt A. Schalper, MD, PhD – Yale School of Medicine

Break

Single Cell Genomics – Using a Finer Lens to Unravel Features of Human Immunity
Alexandra-Chloe Villani, PhD – Massachusetts General Hospital

Mouse Models of the TME
Tyler Jacks, PhD – Koch Institute for Integrative Cancer Research at MIT

Reinvigorating TILs by hyper-oxygenation
Tomasz Zal, PhD – MD Anderson Cancer Center

Comparison of biomarker assay modalities in anti-PD-(L)1 monotherapy: a meta-analysis
Steve Lu, BS – John Hopkins University School of Medicine

Panel Discussion

Closing
Stefani Spranger, PhD – Koch Institute for Integrative Cancer Research at MIT

Team TimIOs – A Pooled Analysis of Durable versus Transient Responders on Immunotherapy Trials
Yana Najjar, MD – University of Pittsburgh
Randy Sweis, MD – University of Chicago

High-dimensional flow cytometry of circulating immune cells predicts clinical responses to combination Immune Checkpoint Blockade (ICB) and Radiotherapy (RT) in Gastroesophageal Cancer (GEC)
Joseph Chao, MD – City of Hope Comprehensive Cancer Center

Fast quality gauging of tumor-infiltrating lymphocytes (TIL) for the treatment of patients with solid cancer
Georgia Paraschoudi, M.Sc. – Champalimaud Foundation

Immunologic biomarkers in a multi-center, single arm, open label Phase II clinical trial of mFOLFOX6 and pembrolizumab in patients with advanced colorectal cancer
Matthew Farren, PhD – Emory University

Deep learning of the immune synapse
John- William Sidhom, MSE – John Hopkins University

Overcoming genetically-based resistance mechanisms to PD-1 blockade
Davis Torrejon, MD – UCLA Hematology-Oncology

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Yinghong Wang, MD, PhD –  University of Texas MD Anderson Cancer Center

Using high dimensional mass cytometry (CyTOF) and machine assisted analysis to detect biomarkers in the immunotherapy of cancer
Carsten Krieg, PhD – Medical University of South Carolina

Development of a next-generation sequencing-based microsatellite instability assay (MSI-NGS) for solid tumor testing
Sean Glenn, PhD – Omniseq, Inc.

Molecular profiling of anti-PD-1 treated melanoma patients reveals importance of assessing neoantigen burden and tumor escape mechanisms for clinical treatment
Sekwon Jang, MD – iNova/Personalis

Preinfusino product doubling time is associated with CAR T cell expansion and outcomes in zumit-1, the pivotal study of axicabtagene cildeneel (axi-ced) in refractory large B cell lymphoma
Frederick Locke, MD - H. Lee Moffitt Cancer Center and Research Institute 

SIRPα blockade increases the activity of multiple myeloid lineage cells, enhances dendritic cell cross-presentation, and aids in remodeling the tumor microenvironment
Jay Hyok Chung – Aduro Biotech

DuoBody-PD-L1x4-1BB combines checkpoint blockade and 4-1BB co-stimulation to promote antigen-specific T-cell stimulation and proliferation
Isil Altintas, PhD – Genmab

Molecular determinants of response to PD-L1 blockade across tumor types
Romain Banchereau – Genentech

CYAD-101: an allogeneic NKG2D CAR T cell therapy using a TCR inhibitory molecule
Alexandre E. Michaux, PhD – Celyad SA

Introduction
Ana Carrizosa Anderson, PhD – Harvard Medical School

LAG-3: Signaling, Function and Potential Impact on Cancer Immunotherapy
Dario A.A. Vignali – University of Pittsburgh

Regulation of Dendritic Cell Function by TIM-3
Brian Ruffell, PhD – Moffitt Cancer Center

Break

Targeting the TIGIT/CD226 Axis in Cancer Immunotherapy
Hassane M. Zarour, MD – UPMC Hillman Cancer Center

4-1BB and Metabolism
Ignacio Melero, MD, PhD – Clinica Universidad de Navarra-FIMA

Remodeling the tumor microenvironment – Targeting Scavenger receptors
Dhifaf Sarhan, PhD – Karolinska Institutet

Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding
Lawrence P. Andrews, PhD – University of Pittsburgh

Closing
Charles G. Drake, MD, PhD – Columbia University Medical Center

Introduction
David S. Hong, MD – University of Texas MD Anderson Cancer Center

Phase 1 study using mogamulizumab (KW-0761) to deplete regulatory T cells in combination with checkpoint inhibitors durvalumab (MEDI4736) or tremelimumab in subjects with advanced solid tumors
Dmitriy Zamarin, MD, PhD – Memorial Sloan Kettering Cancer Center

First-in-human phase 1 dose-escalation trial of the potent and selective next generation transforming growth factor-β receptor type 1 (TGF-βR1) inhibitor LY3200882 in patients with advanced cancers
Timothy Yap, MD – University of Texas MD Anderson Cancer Center

Expert Discussant
Zihai Li, MD, PhD – MUSC Hollings Cancer Center

The GAPVAC approach of actively personalized peptide vaccination for patients with newly diagnosed glioblastoma
Hideho Okada, MD, PhD – University of California, San Francisco, USA and Parker Institute for Cancer Immunotherapy

The Personal Vaccine, NEO-PV-01 with anti-PD1, Induces Neoantigen-Specific De Novo Tumor-Related Immunity in Patients with Advanced Cancer
Siwen Hu-Lieskovan, MD, PhD – Ronald Reagan UCLA Medical Center

Expert Discussant
Drew Pardoll, MD, PhD – Johns Hopkins University

A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma
Diwakar Davar, MD – University of Pittsburgh Department of Medicine

Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma
Adnam Khattak, MD – Perth University

The anti–LAG-3 antibody MK-4280 as monotherapy and in combination with pembrolizumab for advanced solid tumors: first-in-human phase 1 dose-finding study
Nehal Lakhani, MD, PhD – START-Midwest

Phase 1 dose-finding study of the anti–TIGIT antibody MK-7684 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors
Talia Golan – Sheba Medical Center

Expert Discussant
Aung Naing, MD, FACP – University of Texas MD Anderson Cancer Center

Break

Introduction
James L. Gulley, MD, PhD, FACP – National Cancer Institute

NHS/IL15
Marijo Bilusic, MD, PhD – National Cancer Institute, National Institutes of Health

Harnessing Potent Immune Agonist Pathways through Kinetic Engineering
Deborah Charych, PhD

Locoregional Cytokine Immunotherapy
K. Dane Wittrup, PhD – Massachusetts Institute of Technology

Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic Stage IV melanoma
Adi Diab, MD – The University of Texas MD Anderson Cancer Center

Decoy-resistant Interleukin-18 overcomes the soluble immune checkpoint IL-18BP to unlock a potent immunotherapeutic cytokine pathway
Aaron Ring – Yale School of Medicine

Closing
Darrell J. Irvine, PhD – Massachusetts Institute of Technology

Targeting the Adenosinergic Pathway to Improve Combination Immunotherapy
Michele W. Teng, PhD – QIMR Berghofer Medical Research Institute

Enhancement of Oncolytic Virus Immunotherapy Through Vector-Encoded Metabolic Modulation of the Tumor Microenvironment
Greg M. Delgoffe, PhD – University of Pittsburgh

Chronic endoplasmic reticulum stress drives mitochondrial exhaustion of CD8 TILs
Jessica Thaxton, PhD MSCR – Medical University of South Carolina

Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity
Esra Akbay, PhD – University of Texas Southwestern Medical

Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma
Ashley Menk, BS – University of Pittsburgh

Poster Reception

Annual Meeting Organizer Welcome
Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital

Policy Committee Update
Samir N. Khleif, MD – Georgetown University

Introduction
Lisa Butterfield, PhD – University of Pittsburgh

Engineering T cells to Effectively Target Tumors and Overcome Obstacles To Achieving Tumor Eradication
Philip D. Greenberg, MD – Fred Hutchinson Cancer Research Center

Introduction
Crystal Mackall, MD – Stanford University

Pre-Clinical Approaches to CAR NK cell Therapy in Neuroblastoma and Sarcomas
Mitchell Cairo, MD – New York Medical College at Maria Fareri Children's Hospital   

CAR T cell Therapies in Glioblastoma
Christine Brown, PhD – City of Hope National Medical Center

Break

CAR T Cell Therapies in Solid Tumors
Gianpietro Dotti, MD – University of North Carolina, Chapel Hill

TIL Therapy for Melanoma and Beyond - Lessons Learned on Optimal Tumor Rejection Antigens for Solid Tumors
Steven A. Rosenberg, MD, PhD – National Cancer Institute, National Institutes of Health

Tscm-like CD8+ T-cells are Associated with Adoptive TIL Therapy Response and Survival
Matthew Beatty, PhD – Moffitt Cancer Center

Next-generation retroviral vector with membrane-anchored IL-12 to improve adoptive T cell immunotherapy and enhance its safety
Ling Zhang, PhD – National Institutes of Health

Panel Discussion

Closing
Chantale Bernatchez, PhD – University of Texas MD Anderson Cancer Center

National Cancer Institute Update: Immuno-oncology Research at the National Cancer Institute
Norman E. Sharpless, MD – National Cancer Institute

Introduction
Harriet Kluger, MD – Yale University

Clinical and Biomarker Correlates and Management of Common Cellular Therapy Toxicities Including Cytokine Release Syndrome and Neurotoxicity
Eric L. Smith, MD, PhD – Memorial Sloan Kettering Cancer Center

Pembrolizumab in combination with chemoradiotherapy (CRT) in human papilloma virus (HPV)-associated head and neck squamous cell carcinoma (HNSCC)
Steven F. Powell, MD – Sanford Cancer Center

Expert Discussant
Charles Drake, MD, PhD – Columbia University Medical Center

Pharmacodynamic Activity of MEDI1873, a Glucocorticoid-Induced Tumor Necrosis Factor Family-Related protein (GITR) Agonist Molecule, Administered Intravenously to Patients with Advanced Solid Tumors
Nicholas Durham, PhD – MedImmune

Preliminary Biomarker Analysis of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitor
Kai He, MD, PhD

A phase 1b/2 trial of lenvatinib in combination with pembrolizumab in patients with non-small cell lung cancer
Marcia Brose – Abramson Cancer Center of the University

HyPeR: A Phase 1, Dose Escalation Study of Guadecitabine (SGI-110) a Second Generation HypoMethylating Agent in Combination with Pembrolizumab (MK3475) in Patients with Refractory Solid Tumours
Malaka Ameratunga, MBBS – Royal Marsden Hospital

Interleukin-6 gene expression is highly upregulated in immune checkpoint mediated enterocolitis
Daniel Johnson, MD – MD Anderson Cancer Center

Introduction
Lisa H. Butterfield, PhD – University of Pittsburgh

PAK4 inhibition reverses immune cell exclusion and overcomes resistance to checkpoint blockade therapy
Gabriel Abril-Rodriguez, MS – University of California, Los Angeles

Adaptive plasticity of IL10+ and IL35+ regulatory T cells and their cooperative regulation of anti-tumor immunity
Hiroshi Yano, BS – University of Pittsburgh

Expert Discussant
Nicholas P. Restifo, MD – National Cancer Institute

Endoplasmic reticulum stress-induced transcription factor C/EBP homologous protein (Chop) thwarts effector T cell activity in tumors through repression of T-bet
Yu Cao, PhD – H. Lee Moffitt Cancer Center & Research Institute

Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in solid tumors
Kristin Anderson, PhD – Fred Hutchinson Cancer Research Center

Expert Discussant
Patrick Hwu, MD - University of Texas MD Anderson Cancer Center

Break

Introduction
George Plitas, MD – Memorial Sloan Kettering Cancer Center     

Advances in Immunotherapy of Gynecologic Malignancies
Dmitrity Zamarin, MD, PhD – Memorial Sloan Kettering Cancer Center

Increased tumor-resident memory T cells in breast cancer is associated with improved prognosis
Paul Neeson, PhD – Peter MacCallum Cancer Centre

Tumor infiltrating lymphocyte recruitment after peri-lymphatic IRX-2 cytokine immunotherapy in resectable breast cancer and head and neck carcinoma
David Page, MD – Providence Portland Medical Center

Introduction
Dung T. Le, MD – The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

Reprograming the Pancreatic Tumor Microenvironment to Improve Responses to Therapy
David G. DeNardo, PhD – Washington University

Exploiting the Complex Stromal Biology of Pancreas Cancer
Sunil R. Hingorani, MD, PhD – Fred Hutchinson Cancer Research Center

Lipid accumulation in the pancreatic tumor microenvironment drives metabolic exhaustion of CD8+ T cells
Teresa Manzo, PhD – European Institute of Oncology, Milan

The Management of Urothelial Bladder Cancer in the Era of Cancer Immunotherapy
Arjun V. Balar, MD – Perlmutter Cancer Center - New York University Langone Medical Center

Clinical Genomics and Cancer Immunotherapy
Eliezer Van Allen, MD – Dana-Farber Cancer Institute

From the Clinic to the Lab: Investigating Response and Resistance Mechanisms to Immune Checkpoint Therapy
Padmanee Sharma, MD, PhD – University of Texas MD Anderson Cancer Center

Refractory renal cell cancer (RCC) exhibits high adenosine A2A receptor (A2AR) expression and prolonged survival following treatment with the A2AR antagonist, CPI-444
Lawrence Fong, MD – University of California

Off-The-Shelf Engineered NK Cells for The Treatment of Cancer
Katayoun Rezvani, MD, PhD – University of Texas MD Anderson Cancer Center

LSD1 Inhibition Promotes CD141Hi Dendritic Cell Differentiation in Myelodysplastic Syndromes
Pragya Srivastava, PhD – Roswell Park Comprehensive Cancer Center

Introduction
Naiyer A. Rizvi, MD – Columbia University Medical Center

The Influence of the Cancer Genome on Efficacy of Immunotherapy in Lung Cance
Nadeem Riaz, MD, MSc – Memorial Sloan Kettering Cancer Center

Identification and profiling of neoantigen-specific T cells in NSCL cancer patients treated with atezolizumab
Alessandra Nardin, DVM – immunoSCAPE

Peripheral T cell dynamics in resectable NSCLC patients treated with neoadjuvant PD-1 blockade
Jiajia Zhang, MD – MPH – Johns Hopkins University

Introduction
Kavita Dhodapkar, MD – Emory University

Preventing Relapse After CAR T cell Immunotherapy for B cell Malignanices
Terry J. Fry, MD – Children's Hospital of Colorado

Vaccines Targeting Malignant Brain Tumors
Duane A. Mitchell, MD, PhD – University of Florida

Characterization of Anti-Tumor Immune Responses and Effects on Survival of Neoadjuvant Oncolytic Virotherapy in Spontaneous Osteosarcoma
Kelly Makielski, DVM, MS – University of Minnesota

Crystal Mackall, MD – Stanford University

Targeting Regulatory T Cells for Therapeutic Gain: Means and Mechanisms
Sergio A. Quezada, PhD – University College London

The TNFR2 Treg Receptor and Oncogene: Dominant Antagonistic Antibody Targeting for Cancer
Denise L. Faustman, MD, PhD – Harvard Medical School

Lactic acid metabolically supports the high suppressive function of tumor infiltrating regulatory T cells
McLane Watson, BS – University of Pittsburgh

Anti-CTLA4 activation of intratumoral NK cells may contribute to intratumoral Treg depletion
Erica Stone, PhD – Wistar Institute

Neuropilin-1 Stabilizes Human Tregs in Cancer Patients Leading to More Potent Suppressive Function
Christopher A. Chuckran, BS – University of Pittsburgh School of Medicine

Innate Immune Checkpoints and Cancer Immunotherapy
Sourav Ghosh, PhD – Yale School of Medicine

Regulation of Myeloid-Derived Suppressor Cells in Cancer
Dmitry I. Gabrilovich, MD, PhD – The Wistar Institute

Reprogramming suppressive myeloid cells in tumor microenvironment with pepinemab, first-in-class Semaphorin 4D Mab, enhances combination immunotherapy
Greg Lesinski, PhD, MPH – Winship Cancer Institute of Emory University

Using artificial intelligence to distinguish subjects with prostate cancer (PCa) from benign prostate hyperplasia (BPH) through immunophenotyping of MDSCs and lymphocyte cell populations
George A. Dominguez, PhD – Anixa Biosciences

Introduction
Madhav Dhodapkar, MD – Emory University

Role of B cells in Tumors
Tullia C. Bruno, PhD – University of Pittsburgh

Role of B cells in Autoimmunity
Kavita M. Dhodapkar, MD – Emory University

B-cells and tertiary lymphoid structures (TLS) predict response to immune checkpoint blockade (ICB)
Sangeetha Reddy, MD, MSci – MD Anderson Cancer Center

Anti-Tumor Immune Responses in Metastatic Breast Cancer Exceptional Responder Patients
William H. Robinson, MD, PhD – Stanford University School of Medicine

Closing
Tullia C. Bruno, PhD – University of Pittsburgh 

Martin A. Cheever, MD – Fred Hutchinson Cancer Research Center

Introduction
Ignacio Melero, MD, PhD – FIMA-University of Navarra

Next Generation T Cell Bispecific Antibodies and Fusion Proteins for Cancer Immunotherapy
Pablo Umaña, PhD – Roche Glycart AG

Blinatumomab: Can We Improve Efficacy Using Checkpoint Inhibitors
Dirk Nagorsen, MD, PhD – Amgen Inc.

Chimeric Antibodies in AML: Hope or Reality?
Farhad Ravandi, MD – University of Texas MD Anderson Cancer Center

A new immunomodulatory strategy of inhibiting the glyco-immune checkpoint axis with EAGLE technology to treat cancer
Li Peng, PhD – Palleon Pharmaceuticals

FS120 mAb2, a dual agonist bispecific antibody targeting OX40 and CD137, activates T cells in vitro and induces potent, FcγR-independent anti-tumour activity
Miguel Gaspar, PhD – F-star Biotechnology ltd

Immuno-oncology tHERApy with HERA-GITRL: the novel hexavalent human GITR agonist activates T cells and promotes anti-tumor efficacy independent of Fc-functionality
David M. Richards – Apogenix AG

Closing
Farhad Ravandi, MD – University of Texas MD Anderson Cancer Center

Break